CD79A and nasopharyngeal carcinoma: For EBV-based secondary cancer prevention, we should further confirm the effect of population-based NPC screening by EBV-related serum EBV VCA/IgA antibodies and quantitative EBV DNA loading methods, which can be used to identify the high-risk individuals and diagnose early-stage patients.60, 86